Adrenergic bronchodilators: pharmacology and toxicology.
Advances in the understanding of catecholamine metabolism and adrenergic receptor biochemistry have permitted the development of a number of potent and relatively selective sympathomimetic drugs that are active after oral administration as well as when administered by injection or inhalation. Their toxicity derives solely from their effect as adrenergic agonists, and their appropriate use is based on understanding their pharmacology.
Reed
C E
CE
D000014:Abnormalities, Drug-Induced / Q000209:etiology; D000322:Adrenergic Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents; D002394:Catechol O-Methyltransferase / Q000378:metabolism; D002395:Catecholamines / Q000502:physiology*; D002455:Cell Division / Q000187:drug effects; D005965:Glucuronates / Q000378:metabolism; D020723:Glucuronic Acid; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008995:Monoamine Oxidase / Q000378:metabolism; D009132:Muscles / Q000187:drug effects; D012472:Salivation / Q000187:drug effects; D013329:Structure-Activity Relationship; D013431:Sulfates / Q000378:metabolism
D000322:Adrenergic Agonists; D001993:Bronchodilator Agents; D002395:Catecholamines; D005965:Glucuronates; D013431:Sulfates; D020723:Glucuronic Acid; D008995:Monoamine Oxidase; D002394:Catechol O-Methyltransferase